We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Play it again Sam

6 October 2008 By Robert Cyran

M&A bankers may be in hibernation, but biotechs with saleable drugs are keeping big pharma up nights. Eli Lilly has offered a full price for Imclone, an asset with some strings attached. Rival suitor and natural partner BristolMyers Squibb isn t out of the running.

This content is for Subscribers only

or
If you need assistance please email breakingviews.clientsupport@thomsonreuters.com
 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)

We need you to verify your email address to continue. Please check your email/junk folder for our verification request.

Click here to resend the verification email.